Vaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of “Buy” by Brokerages

Shares of Vaxcyte, Inc. (NASDAQ:PCVX) have been given an average rating of “Buy” by the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $147.50.

Several equities analysts recently commented on PCVX shares. Leerink Partners increased their price objective on shares of Vaxcyte from $106.00 to $153.00 and gave the company an “outperform” rating in a research note on Tuesday, September 3rd. Jefferies Financial Group raised their price objective on Vaxcyte from $108.00 to $129.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. BTIG Research boosted their price objective on Vaxcyte from $98.00 to $160.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Needham & Company LLC increased their target price on Vaxcyte from $95.00 to $140.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Finally, Bank of America lifted their price target on Vaxcyte from $101.00 to $140.00 and gave the company a “buy” rating in a research note on Wednesday, September 4th.

Vaxcyte Price Performance

Shares of NASDAQ:PCVX opened at $112.66 on Wednesday. Vaxcyte has a 1 year low of $45.61 and a 1 year high of $121.06. The stock has a market capitalization of $12.57 billion, a price-to-earnings ratio of -24.07 and a beta of 0.99. The company’s 50 day simple moving average is $104.02 and its 200 day simple moving average is $83.43.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($1.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.14) by $0.04. During the same period in the prior year, the business posted ($0.70) earnings per share. As a group, analysts anticipate that Vaxcyte will post -4.33 EPS for the current fiscal year.

Insider Buying and Selling

In other news, SVP Elvia Cowan sold 5,000 shares of the company’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $107.67, for a total value of $538,350.00. Following the sale, the senior vice president now directly owns 12,723 shares of the company’s stock, valued at approximately $1,369,885.41. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, SVP Elvia Cowan sold 5,000 shares of Vaxcyte stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $107.67, for a total value of $538,350.00. Following the completion of the transaction, the senior vice president now directly owns 12,723 shares of the company’s stock, valued at approximately $1,369,885.41. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Andrew Guggenhime sold 42,000 shares of the company’s stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $115.39, for a total value of $4,846,380.00. Following the sale, the chief financial officer now owns 90,383 shares in the company, valued at approximately $10,429,294.37. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 92,098 shares of company stock valued at $9,937,773 over the last ninety days. 3.10% of the stock is owned by company insiders.

Institutional Trading of Vaxcyte

Several large investors have recently modified their holdings of the stock. Harbor Capital Advisors Inc. increased its holdings in shares of Vaxcyte by 392.4% during the second quarter. Harbor Capital Advisors Inc. now owns 40,342 shares of the company’s stock valued at $3,046,000 after acquiring an additional 32,149 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Vaxcyte by 18.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,176,181 shares of the company’s stock worth $216,966,000 after buying an additional 498,359 shares during the last quarter. Swiss National Bank lifted its stake in shares of Vaxcyte by 20.4% in the first quarter. Swiss National Bank now owns 178,000 shares of the company’s stock valued at $12,159,000 after buying an additional 30,100 shares in the last quarter. Allspring Global Investments Holdings LLC increased its position in shares of Vaxcyte by 109.7% during the first quarter. Allspring Global Investments Holdings LLC now owns 47,388 shares of the company’s stock worth $3,237,000 after acquiring an additional 24,785 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of Vaxcyte by 2.0% in the 4th quarter. Vanguard Group Inc. now owns 8,452,371 shares of the company’s stock worth $530,809,000 after acquiring an additional 168,125 shares during the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.